September 20, 2006

> Watch Video High Low

MS Treatment High doses of a cancer drug have given some Multiple Sclerosis patients their life back.

http://www.geraldoatlarge.com/video-archive.php

---

B3 multiple sclerosis mice

Daily Nicotinamide Shots May Protect Multiple Sclerosis Patients ...
Medical News Today - UK
Giving multiple sclerosis (MS) patients a daily shot of nicotinamide ... who managed to do this with mice with Experimental ... Nicotinamide is a form of vitamin B3. ...
See all stories on this topic

B Vitamin Prevents MS Disability in Mice
MedPage Today - Little Falls,NJ,USA
... and its close relative, vitamin B3, is already ... the doses used in the mice would translate ... The study was financed by National Multiple Sclerosis Society and the ...

Vitamin B3 may help patients with Multiple sclerosis
Earthtimes.org - USA
... which is a form of vitamin B3, may help individuals who are suffering from Multiple sclerosis. The study, which was conducted on mice suffering from a disease ...
See all stories on this topic

---

tysabri

RU-486, Why The Special Treatment?
Stop the ACLU - New Cumberland,PA,USA
by Oak Leaf on 09-20-06 @ 2:38 pm Filed under Abortion, News. Tysabri, used to treat MS, was pulled from the market following reports of one death. US Sen. ...

---

Pfizer's Lyrica(R) Approved In Europe For Difficult-to-Treat Nerve Pain Medical News Today Tue, 19 Sep 2006 0:10 AM PDT Pfizer Inc said today that the European Commission approved Lyrica(R) (pregabalin capsules) to treat central neuropathic (nerve) pain. This new approval broadens the current range of neuropathic pain that Lyrica is approved to treat in Europe to include nerve pain associated with conditions such as spinal cord injury, stroke, and multiple sclerosis. [click link for full article]

Positive Results for Opexa in Ongoing MS Study RedNova Mon, 18 Sep 2006 12:19 PM PDT Opexa Therapeutics has said that after positive data from a phase I/II trial assessing Tovaxin for the treatment of multiple sclerosis, it has initiated a phase IIb study. Phase I/II trials indicated that after 12 months, patients exhibited a relapse rate reduction of more than 90%.

Pfizer's Lyrica(R) Approved in Europe for Difficult-to-Treat Nerve Pain campus med Mon, 18 Sep 2006 1:06 PM PDT New York (ots/PRNewswire) - - Lyrica's neuropathic pain indication broadened to include central nerve pain; Central nerve pain is associated with conditions such as spinal cord injury, stroke, and multiple sclerosis - A robust and unprecedented clinical program involving more than 10,000 patients supports Lyrica's efficacy and safety in treating a broad range of neurological disorders - Medical

131 now have marijuana cards
The Providence Journal Mon, 18 Sep 2006 9:49 PM PDT
When Rhonda O'Donnell took her first puff of marijuana -- her first, that is, since her teen years -- the effect was immediate.